I'm not sure I've ever gotten a more enthusiastic comment on a study I'm covering:
"I’m always cautious about how I describe advances in cancer treatment because I don’t want to prematurely raise hope in patients. In this case here, this is huge."
www.the-scientist.com/daraxonrasib...
An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic and other cancers.
